A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

Current Oncology

Volumn 17, Issue 2, 2010, Pages 24-29

  Chin, S N ^a   Wang, L ^a   Moore, M ^a   Sridhar, S S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory; Prostate cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CANCER; QUALITY OF LIFE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SYMPTOM; TASTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 77950562879     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i2.482     Document Type: Article

References (10)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto: Canadian Cancer Society; 2008. [Available online at: http://www.cancer.ca/canada-wide/aboutcancer/cancerstatistics/~/media/CCS/Canadawide/FilesList/Englishfilesheading/pdf not in publications section/Canadian Cancer Society Statistics PDF 2008_614137951.ashx; cited February 14, 2010]
2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Tannock IF, de Wit R, Berry WR, et al. on behalf of the tax 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the tax 327 study. J Clin Oncol 2008;26:242-5.
6. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase ii clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
7. Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008;44:1193-7.
8. Howard DN, Chambers C, Cusano F. Efficacy vs. effectiveness-docetaxel and prednisone in hormone refractory prostate cancer. J Oncol Pharm Pract 2008;14:45-9.
9. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF on behalf of the tax 327 Investigators. Survival and psa response of patients in the tax 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.
10. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (s) demonstrates significant clinical benefits for the treatment of patients with hrpc: results of a randomized phase iii trial (abstract 5019). Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31837; cited February 10, 2010]